Mechanistic perspectives on differential mitochondrial-based neuroprotective effects of several carnitine forms in Alzheimer’s disease in vitro model
- 24 June 2021
- journal article
- research article
- Published by Springer Nature in Archives of Toxicology
- Vol. 95 (8) , 2769-2784
Abstract
Mitochondrial deregulation has emerged as one of the earliest pathological events in Alzheimer’s disease (AD), the most common age-related neurodegenerative disorder. Improvement of mitochondrial function in AD has been considered a relevant therapeutic approach. l-carnitine (LC), an amino acid derivative involved in the transport of long-chain fatty acids into mitochondria, was previously demonstrated to improve mitochondrial function, having beneficial effects in neurological disorders; moreover, acetyl-l-carnitine (ALC) is currently under phase 4 clinical trial for AD (ClinicalTrials.gov NCT01320527). Thus, in the present study, we investigated the impact of different forms of carnitines, namely LC, ALC and propionyl-l-carnitine (PLC) on mitochondrial toxicity induced by amyloid-beta peptide 1–42 oligomers (AβO; 1 μM) in mature rat hippocampal neurons. Our results indicate that 5 mM LC, ALC and PLC totally rescued the mitochondrial membrane potential and alleviated both the decrease in oxygen consumption rates and the increase in mitochondrial fragmentation induced by AβO. These could contribute to the prevention of neuronal death by apoptosis. Moreover, only ALC ameliorated AβO-evoked changes in mitochondrial movement by reducing the number of stationary mitochondria and promoting reversal mitochondrial movement. Data suggest that carnitines (LC, ALC and PLC) may act differentially to counteract changes in mitochondrial function and movement in neurons subjected to AβO, thus counteracting AD-related pathological phenotypes.Keywords
Funding Information
- AlfaSigma BV Pharmaceutical (----)
- European Regional Development Fund (CENTRO-01-0145-FEDER-000012-HealthyAging2020)
- Fundação para a Ciência e a Tecnologia (POCI-01-0145-FEDER-007440, UIDB/04539/2020, SFRH/BPD/99219/2013)
This publication has 66 references indexed in Scilit:
- Engineering HIV-1-Resistant T-Cells from Short-Hairpin RNA-Expressing Hematopoietic Stem/Progenitor Cells in Humanized BLT MicePLOS ONE, 2012
- HDAC6 Inhibitor Blocks Amyloid Beta-Induced Impairment of Mitochondrial Transport in Hippocampal NeuronsPLOS ONE, 2012
- Amyloid-β Peptide Binds to Cytochrome C Oxidase Subunit 1PLOS ONE, 2012
- Acetyl- l -Carnitine Activates the Peroxisome Proliferator-Activated Receptor-γ Coactivators PGC-1α/PGC-1β–Dependent Signaling Cascade of Mitochondrial Biogenesis and Decreases the Oxidized Peroxiredoxins Content in Old Rat LiverRejuvenation Research, 2012
- Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's diseaseHuman Molecular Genetics, 2011
- Metabolic Agents that Enhance ATP can Improve Cognitive Functioning: A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and l-CarnitineNutrients, 2011
- Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damageHuman Molecular Genetics, 2011
- Up-regulation of kinesin light-chain 1 gene expression by acetyl-l-carnitine: Therapeutic possibility in Alzheimer's diseaseNeurochemistry International, 2008
- Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteinsProceedings of the National Academy of Sciences, 2008
- The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristaeProceedings of the National Academy of Sciences, 2008